Anfarm

Anfarm is a long-established, privately-held Greek generic drug manufacturer with a strong international footprint. Its core business model revolves around the production and global distribution of generic pharmaceuticals, supported by significant in-house lyophilization capacity and technology transfer services for third parties. The company leverages its EU GMP certification to access regulated and emerging markets, positioning itself as a contract development and manufacturing organization (CDMO) in addition to its branded generic business. Its strategy focuses on expanding its pipeline of value-added generic products and its third-party service offerings.

EU GMP pharmaceutical manufacturing with specialized high-capacity lyophilization (freeze-drying) and technology transfer services for formulation and analytical development.

Anfarm competes with large multinational generic manufacturers (e.g., Teva, Sandoz) and other regional EU GMP-certified CDMOs. Its competitive advantages are its specialized lyophilization capacity, cost-effective Greek base, and long-standing relationships in emerging markets. It differentiates through a hybrid model of own-brand generics and contract services.